Particularly, spatial transcriptomics combined with exosome-tracking approaches [211] enable precise localization of exosome–immune interactions in the tumor microenvironment, which could be applied to validate CDH2-centered redox licensing and EMT–CSC coupling. This evidence concerns the gene CDH2 and neoplasm.